Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 19/20 | 0.59 |
| ▸ | CCR3 | P51677 | 19/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 16/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4140781 | 0.88 | HRH1 (0.64) | HRH1CCR3KCNH2 | |
| SCHEMBL6620599 | 0.85 | HRH1 (0.59) | HRH1CCR3KCNH2 | |
| SCHEMBL5462103 | 0.85 | GPR119 (0.58) | HRH1CCR3KCNH2 | |
| SCHEMBL3939817 | 0.83 | HRH1 (0.61) | HRH1CCR3KCNH2 | |
| SCHEMBL3940636 | 0.83 | HRH1 (0.61) | HRH1CCR3KCNH2 | |
| SCHEMBL3282383 | 0.82 | GPR119 (0.59) | HRH1CCR3KCNH2 | |
| SCHEMBL1943087 | 0.81 | CCR2 (0.57) | KCNH2 | |
| SCHEMBL5189718 | 0.80 | HRH1 (0.68) | HRH1CCR3KCNH2 | |
| SCHEMBL12539489 | 0.80 | CCR2 (0.73) | KCNH2 | |
| SCHEMBL5194646 | 0.78 | CCR3 (0.47) | HRH1CCR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517989-B2 | Piperidine derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2009-04-14 | — | — | US | disclosed |
| US-20090069325-A1 | Piperidine Derivatives Useful as Modulators of Chemokine Receptor Activity | ASTRAZENECA AB (SE) | 2009-03-12 | — | — | US | disclosed |
| US-20050176708-A1 | Piperidine derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2005-08-11 | — | — | US | disclosed |
| EP-1487793-A1 | PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003078395-A1 | PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176708-A1 | Piperidine derivatives useful as modulators of chemokine receptor activity | CCR3, CCR1, ACKR3 | HRH1 46/4885CCR3 1/4885KCNH2 2355/4885 |
| US-20090069325-A1 | Piperidine Derivatives Useful as Modulators of Chemokine Receptor Activity | CCR3, CCR1, CCR5 | HRH1 37/4885CCR3 1/4885KCNH2 2489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.